Comparison of Biolimus A9-Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions A Randomized Long Drug-Eluting Stent V Trial

  • Lee, Jong-Young
  • Park, Duk-Woo
  • Kim, Young-Hak
  • Ahn, Jung-Min
  • Kim, Won-Jang
  • ... Lee, Bong-Ki
  • 외 18명
Citations

WEB OF SCIENCE

29
Citations

SCOPUS

32

초록

Background Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo percutaneous coronary intervention. The current study, therefore, evaluated 2 innovative drug-eluting stents for the management of long-lesion coronary artery disease. Methods and Results This randomized, multicenter, prospective trial, called the Long Drug-Eluting Stent (LONG-DES) V trial, compared the biodegradable polymer-based biolimus A9-eluting stent (BES) and the durable polymer-based platinum chromium everolimus-eluting stent (PtCr-EES) in 500 patients with long (25 mm) coronary lesions. The primary end point of the trial was in-segment late luminal loss at the 9-month angiographic follow-up. The BES and PtCr-EES groups had similar baseline characteristics, with a slightly shorter lesion length in the BES group versus the PtCr-EES group (29.2412.17 versus 32.2713.84 mm; P=0.016). In-segment late luminal loss was comparable between the 2 groups at the 9-month angiographic follow-up (BES, 0.14 +/- 0.38 versus PtCr-EES, 0.11 +/- 0.37 mm; difference, 0.031; 95% confidence interval, -0.053 to 0.091; P=0.03 for a noninferiority margin of 0.11, P=0.45 for superiority), as was in-stent late luminal loss (0.20 +/- 0.41 versus 0.24 +/- 0.38 mm; P=0.29). The incidence of in-segment (6.1% versus 4.9%; P=0.63) and in-stent (3.7% versus 4.9%; P=0.59) binary restenosis was also similar between the groups. There was no significant between-group difference in the rate of composite outcome of death, myocardial infarction, and target vessel revascularization (41, 16.7% in BES versus 42, 16.5% in PtCr-EES; P=0.94). Conclusions BES and PtCr-EES implantation showed analogous angiographic and clinical outcomes for patients with de novo long coronary lesions. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT01186120.

키워드

angioplastybiolimuscoronary artery diseaseeverolimusstentsNON-INFERIORITY TRIALRESTENOSISOUTCOMESDISEASEIMPLANTATIONTHROMBOSIS
제목
Comparison of Biolimus A9-Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions A Randomized Long Drug-Eluting Stent V Trial
저자
Lee, Jong-YoungPark, Duk-WooKim, Young-HakAhn, Jung-MinKim, Won-JangKang, Soo-JinLee, Seung-WhanLee, Cheol WhanPark, Seong-WookYun, Sung-CheolYang, Tae-HyunLee, Bong-KiLee, Nae-HeeYang, Joo-YoungShin, Won-YongPark, Hun SikKim, Kee-SikHur, Seung HoLee, Sung YunPark, Jong-SeonChoi, Yun SeokLee, Seung UkHer, Sung-HoPark, Seung-Jung
DOI
10.1161/CIRCINTERVENTIONS.113.000841
발행일
2014-06
유형
Article
저널명
Circulation: Cardiovascular Interventions
7
3
페이지
322 ~ 329